Read by QxMD icon Read

Michael J. Pencina

Benjamin A Goldstein, Ann Marie Navar, Michael J Pencina
No abstract text is available yet for this article.
October 12, 2016: JAMA Cardiology
Laine E Thomas, Michael J Pencina
No abstract text is available yet for this article.
October 12, 2016: JAMA Cardiology
Michael J Pencina, Jason P Fine, Ralph B D'Agostino
Discrimination slope, defined as the slope of a linear regression of predicted probabilities of event derived from a prognostic model on the binary event status, has recently gained popularity as a measure of model performance. It is as a building block for the integrated discrimination improvement that equals the difference in discrimination slopes between the two models being compared. Several authors have pointed out that it does not make sense to apply the integrated discrimination improvement and discrimination slope when working with mis-calibrated models, whereas others have raised concerns about the ability of improving discrimination slope without adding new information...
October 3, 2016: Statistics in Medicine
Timothy P Murphy, Christopher J Cooper, Karol M Pencina, Ralph D'Agostino, Joseph Massaro, Donald E Cutlip, Kenneth Jamerson, Alan H Matsumoto, William Henrich, Joseph I Shapiro, Katherine R Tuttle, David J Cohen, Michael Steffes, Qi Gao, D Christopher Metzger, William B Abernethy, Stephen C Textor, John Briguglio, Alan T Hirsch, Sheldon Tobe, Lance D Dworkin
: Randomized clinical trials have not shown an additional clinical benefit of renal artery stent placement over optimal medical therapy alone. However, studies of renal artery stent placement have not examined the relationship of albuminuria and treatment group outcomes. The CORAL study (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) is a prospective clinical trial of 947 participants with atherosclerotic renal artery stenosis randomized to optimal medical therapy with or without renal artery stent which showed no treatment differences (3(5...
November 2016: Hypertension
Emily C O'Brien, Ying Xian, Haolin Xu, Jingjing Wu, Jeffrey L Saver, Eric E Smith, Lee H Schwamm, Eric D Peterson, Mathew J Reeves, Deepak L Bhatt, Lesley Maisch, Deidre Hannah, Brianna Lindholm, DaiWai Olson, Janet Prvu Bettger, Michael Pencina, Adrian F Hernandez, Gregg C Fonarow
BACKGROUND AND PURPOSE: Stroke survivors identify home-time as a high-priority outcome; there are limited data on factors influencing home-time and home-time variability among discharging hospitals. METHODS: We ascertained home-time (ie, time alive out of a hospital, inpatient rehabilitation facility, or skilled nursing facility) at 90 days and 1-year post discharge by linking data from Get With The Guidelines-Stroke Registry patients (≥65 years) to Medicare claims...
October 2016: Stroke; a Journal of Cerebral Circulation
Ann Marie Navar, Michael J Pencina, Eric D Peterson
Importance: The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated the benefit of lowering systolic blood pressure (SBP) to 120 mm Hg, yet other trials, such as Heart Outcomes Prevention Evaluation-3 (HOPE-3), did not find consistent benefit. How to incorporate these results into the treatment of those with elevated SBP in the general population is not clear. Objectives: To assess the representativeness of SPRINT and HOPE-3 relative to patients in the United States and to explore the cardiovascular disease (CVD) risk profiles of various populations with elevated SBP...
September 7, 2016: JAMA Cardiology
Ann Marie Navar, Michael J Pencina, Eric D Peterson
No abstract text is available yet for this article.
August 9, 2016: JAMA: the Journal of the American Medical Association
Christoph P Hornik, Daniel K Benjamin, P Brian Smith, Michael J Pencina, Adriana H Tremoulet, Edmund V Capparelli, Jessica E Ericson, Reese H Clark, Michael Cohen-Wolkowiez
OBJECTIVE: To evaluate the relationship between ampicillin dosing, exposure, and seizures. STUDY DESIGN: This was a retrospective observational cohort study of electronic health record (EHR) data combined with pharmacokinetic model derived drug exposure predictions. We used the EHR from 348 Pediatrix Medical Group neonatal intensive care units from 1997 to 2012. We included all infants 24-41 weeks gestational age, 500-5400 g birth weight, first exposed to ampicillin prior to 25 days postnatal age...
August 10, 2016: Journal of Pediatrics
Piotr Chruściel, Amirhossein Sahebkar, Magdalena Rembek-Wieliczko, Maria-Corina Serban, Sorin Ursoniu, Dimitri P Mikhailidis, Steven R Jones, Svetlana Mosteoru, Michael J Blaha, Seth S Martin, Jacek Rysz, Peter P Toth, Gregory Y H Lip, Michael J Pencina, Kausik K Ray, Maciej Banach
BACKGROUND AND AIMS: The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs). METHODS: Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. RESULTS: In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0...
October 2016: Atherosclerosis
Neha J Pagidipati, Michael Pencina, Allan D Sniderman
No abstract text is available yet for this article.
May 1, 2016: JAMA Cardiology
Darren K McGuire, Frans Van de Werf, Paul W Armstrong, Eberhard Standl, Joerg Koglin, Jennifer B Green, M Angelyn Bethel, Jan H Cornel, Renato D Lopes, Sigrun Halvorsen, Giuseppe Ambrosio, John B Buse, Robert G Josse, John M Lachin, Michael J Pencina, Jyotsna Garg, Yuliya Lokhnygina, Rury R Holman, Eric D Peterson
IMPORTANCE: Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and secondary composite atherosclerotic cardiovascular (CV) outcomes in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). OBJECTIVE: To assess the association of sitagliptin use with hospitalization for HF (hHF) and related outcomes...
May 1, 2016: JAMA Cardiology
Ervin R Fox, Tandaw E Samdarshi, Solomon K Musani, Michael J Pencina, Jung Hye Sung, Alain G Bertoni, Vanessa Xanthakis, Pelbreton C Balfour, Satya S Shreenivas, Carolyn Covington, Philip R Liebson, Daniel F Sarpong, Kenneth R Butler, Thomas H Mosley, Wayne D Rosamond, Aaron R Folsom, David M Herrington, Ramachandran S Vasan, Herman A Taylor
IMPORTANCE: Cardiovascular risk assessment is a fundamental component of prevention of cardiovascular disease (CVD). However, commonly used prediction models have been formulated in primarily or exclusively white populations. Whether risk assessment in black adults is dissimilar to that in white adults is uncertain. OBJECTIVES: To develop and validate risk prediction models for CVD incidence in black adults, incorporating standard risk factors, biomarkers, and subclinical disease...
April 1, 2016: JAMA Cardiology
Jerry C Lee, Tomasz Zdrojewski, Michael J Pencina, Adam Wyszomirski, Mateusz Lachacz, Grzegorz Opolski, Piotr Bandosz, Marcin Rutkowski, Zbigniew Gaciong, Bogdan Wyrzykowski, Ann M Navar
IMPORTANCE: The American College of Cardiology/American Heart Association (ACC/AHA) guidelines for the management of blood cholesterol and the current European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines differ in how they identify adults in need of statin therapy; furthermore, it is unclear how this difference translates into numbers and characteristics of patients recommended for treatment. OBJECTIVE: To determine the effect of the ACC/AHA and ESC/EAS cholesterol guidelines when applied to a population-based sample...
September 1, 2016: JAMA Cardiology
Michael J Pencina, Ewout W Steyerberg, Ralph B D'Agostino
The net reclassification improvement (NRI) is an attractively simple summary measure quantifying improvement in performance because of addition of new risk marker(s) to a prediction model. Originally proposed for settings with well-established classification thresholds, it quickly extended into applications with no thresholds in common use. Here we aim to explore properties of the NRI at event rate. We express this NRI as a difference in performance measures for the new versus old model and show that the quantity underlying this difference is related to several global as well as decision analytic measures of model performance...
July 18, 2016: Statistics in Medicine
Benjamin A Goldstein, Michael J Pencina, Maria E Montez-Rath, Wolfgang C Winkelmayer
OBJECTIVE: Electronic health records (EHRs) are a resource for "big data" analytics, containing a variety of data elements. We investigate how different categories of information contribute to prediction of mortality over different time horizons among patients undergoing hemodialysis treatment. MATERIAL AND METHODS: We derived prediction models for mortality over 7 time horizons using EHR data on older patients from a national chain of dialysis clinics linked with administrative data using LASSO (least absolute shrinkage and selection operator) regression...
June 29, 2016: Journal of the American Medical Informatics Association: JAMIA
Maciej Banach, Maria-Corina Serban, Amirhossein Sahebkar, Hector M García-García, Dimitri P Mikhailidis, Seth S Martin, Daniel Brie, Jacek Rysz, Peter P Toth, Steven R Jones, Rani K Hasan, Svetlana Mosteoru, Mahmoud Al Rifai, Michael J Pencina, Patrick W Serruys
AIMS: Several studies have suggested good procedural and similar clinical outcomes between everolimus-eluting Absorb bioresorbable stents (BRS) versus conventional drug-eluting stents (DES), but the evidence is not definitive. Our aim was to perform a systematic review and meta-analysis to investigate the effects of BRS versus conventional drug-eluting and bare metallic stents on the cardiovascular endpoints and all-cause mortality. METHODS AND RESULTS: The follow-up in the included studies was up to 13 months...
June 12, 2016: EuroIntervention
Katherine R Tuttle, Lance D Dworkin, William Henrich, Barbara A Greco, Michael Steffes, Sheldon Tobe, Joseph I Shapiro, Kenneth Jamerson, Asya Lyass, Karol Pencina, Joseph M Massaro, Ralph B D'Agostino, Donald E Cutlip, Timothy P Murphy, Christopher J Cooper
BACKGROUND AND OBJECTIVES: Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (from May of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage ≥3 CKD...
July 7, 2016: Clinical Journal of the American Society of Nephrology: CJASN
Benjamin A Goldstein, Ann Marie Navar, Michael J Pencina, John Pa Ioannidis
OBJECTIVE: Electronic health records (EHRs) are an increasingly common data source for clinical risk prediction, presenting both unique analytic opportunities and challenges. We sought to evaluate the current state of EHR based risk prediction modeling through a systematic review of clinical prediction studies using EHR data. METHODS: We searched PubMed for articles that reported on the use of an EHR to develop a risk prediction model from 2009 to 2014. Articles were extracted by two reviewers, and we abstracted information on study design, use of EHR data, model building, and performance from each publication and supplementary documentation...
May 17, 2016: Journal of the American Medical Informatics Association: JAMIA
Meredith E Clement, Lawrence P Park, Ann Marie Navar, Nwora Lance Okeke, Michael J Pencina, Pamela S Douglas, Susanna Naggie
BACKGROUND: Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are associated with increased risk of cardiovascular disease (CVD). The potential impact of recently updated cholesterol guidelines on treatment of HIV- and HCV-infected veterans is unknown. METHODS: We performed a retrospective cohort study to assess statin use and recommendations among 13 579 HIV-infected, 169 767 HCV-infected, and 6628 HIV/HCV-coinfected male veterans aged 40-75 years...
August 1, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Michael J Pencina, Eric D Peterson
No abstract text is available yet for this article.
April 26, 2016: JAMA: the Journal of the American Medical Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"